阿帕替尼联合新辅助化疗对局部晚期结肠癌的临床疗效研究

doi:10.3877/cma.j.issn.1674-0793.2024.03.005

目的

探讨阿帕替尼联合新辅助化疗对局部晚期结肠癌治疗中的临床疗效和不良事件。

方法

设计前瞻性单臂试验，选择2019年1月至2020年12月联勤保障部队第九八〇医院收治的局部晚期大肠癌患者30例，给予阿帕替尼联合新辅助化疗后接受手术及辅助治疗，评估新辅助疗效、生存情况及治疗后不良事件。

结果

新辅助治疗后患者完全缓解（CR）、部分缓解（PR）、疾病稳定（SD）以及疾病进展（PD）的例数分别为0例（0）、17例（56.7%）、12例（40.0%）和1例（3.3%），客观缓解率为56.7%（17/30），疾病控制率为96.7%（29/30）。与治疗前相比，治疗后临床T分期、N分期和TNM分期均有所降低（均P<0.001）。6例（20.0%）实现了术后病理完全缓解（pCR），28例（93.3%）实现了R0切除。生存分析提示患者中位无进展生存期和总生存期分别为26.3个月和27.7个月。围手术期的不良事件多数为轻度（1~2级），少数为3级不良事件，未发现4级不良事件。

结论

新辅助治疗中阿帕替尼联合化疗在局部晚期大肠癌中显示出良好疗效。该方案严重不良事件发生率较低，是值得进一步探究的治疗策略。

关键词: 结肠肿瘤, 阿帕替尼, 血管内皮细胞生长因子受体, 新辅助治疗

Objective

To investigate the clinical efficacy and adverse events of Apatinib combined with neoadjuvant chemotherapy in the treatment of locally advanced colon cancer.

Methods

A prospective single-arm trial was designed. Thirty cases with locally advanced colon cancer admitted to the 980th Hospital of the Joint Logistics Support Force from January 2019 to December 2020 were selected. The patients received surgery and adjuvant therapy after administration of apatinib in combination with neoadjuvant chemotherapy, while neoadjuvant efficacy, survival, and adverse events after treatment were evaluated.

Results

The incidence of complete response (CR), partial response (PR), stable disease (SD) and progressive disease (PD) after neoadjuvant chemotherapy was 0 (0), 17 (56.7%), 12 (40.0%) and 1 (3.3%), respectively. The objective response rate was 56.7% and the disease control rate was 96.7%. Clinical T-stage, N-stage, and TNM-stage were reduced after treatment compared to the levels before treatment (all P<0.001). Pathological complete remission (pCR) was achieved in 6 (20.0%) patients and R0 resection was achieved in 28 (93.3%) patients. Survival analysis showed the median progression free survival (PFS) and overall survival (OS) were 26.3 months and 27.7 months, respectively. During perioperative treatment, most of the observed adverse events were mild (grade 1-2); only a few grade 3 adverse events were observed and no grade 4 adverse events were identified.

Conclusions

Neoadjuvant therapy with Apatinib in combination with chemotherapy has shown good efficacy in locally advanced colon cancer. This regimen has a low rate of serious adverse events and is a therapeutic strategy worthy of further investigation.

Key words: Colon neoplasms, Apatinib, Vascular endothelial growth factor receptor, Neoadjuvant therapy

表1 30例局部晚期结肠癌患者新辅助治疗前后的临床分期[例(%)]

临床分期	治疗前	治疗后	Z值	P值
T分期			3.755	<0.001
cT2	0(0)	7(23.3)
cT3	4(13.3)	9(30.0)
cT4	26(86.7)	14(46.7)
N分期			5.166	<0.001
cN0	0(0)	15(50.0)
cN1	12(40.0)	10(33.3)
cN2a	13(43.3)	4(13.3)
cN2b	5(16.7)	1(3.3)
TNM分期			3.800	<0.001
Ⅰ	0(0)	7(23.3)
Ⅱ	0(0)	12(40.0)
Ⅲ	30(100.0)	10(33.3)
Ⅳ	0(0)	1(3.3)

表1 30例局部晚期结肠癌患者新辅助治疗前后的临床分期[例(%)]

临床分期	治疗前	治疗后	Z值	P值
T分期			3.755	<0.001
cT2	0(0)	7(23.3)
cT3	4(13.3)	9(30.0)
cT4	26(86.7)	14(46.7)
N分期			5.166	<0.001
cN0	0(0)	15(50.0)
cN1	12(40.0)	10(33.3)
cN2a	13(43.3)	4(13.3)
cN2b	5(16.7)	1(3.3)
TNM分期			3.800	<0.001
Ⅰ	0(0)	7(23.3)
Ⅱ	0(0)	12(40.0)
Ⅲ	30(100.0)	10(33.3)
Ⅳ	0(0)	1(3.3)

图1 局部晚期结肠癌患者无进展生存期的Kaplan-Meier曲线

图2 局部晚期结肠癌患者总生存期的Kaplan-Meier曲线

表2 30例局部晚期结肠癌患者围手术期不良事件[例(%)]

不良事件	所有级别	1级	2级	3级	4级
血液学事件
白细胞减少	19(63.3)	4(13.3)	12(40.0)	3(10.0)	0(0)
血小板减少	16(53.3)	13(43.3)	2(6.7)	1(3.3)	0(0)
贫血	11(36.7)	5(16.7)	5(16.7)	1(3.3)	0(0)
非血液学事件
恶心	19(63.3)	10(33.3)	8(26.7)	1(3.3)	0(0)
疲劳	18(60.0)	13(43.3)	5(16.7)	0(0)	0(0)
转氨酶升高	13(43.3)	10(33.3)	3(10.0)	0(0)	0(0)
呕吐	10(33.3)	7(23.3)	2(6.7)	1(3.3)	0(0)
蛋白尿	11(36.7)	7(23.3)	3(10.0)	1(3.3)	0(0)
高血压	10(33.3)	8(26.7)	2(6.7)	0(0)	0(0)
腹泻	3(10.0)	2(6.7)	1(3.3)	0(0)	0(0)
手足综合征	2(6.7)	1(3.3)	1(3.3)	0(0)	0(0)

表2 30例局部晚期结肠癌患者围手术期不良事件[例(%)]

不良事件	所有级别	1级	2级	3级	4级
血液学事件
白细胞减少	19(63.3)	4(13.3)	12(40.0)	3(10.0)	0(0)
血小板减少	16(53.3)	13(43.3)	2(6.7)	1(3.3)	0(0)
贫血	11(36.7)	5(16.7)	5(16.7)	1(3.3)	0(0)
非血液学事件
恶心	19(63.3)	10(33.3)	8(26.7)	1(3.3)	0(0)
疲劳	18(60.0)	13(43.3)	5(16.7)	0(0)	0(0)
转氨酶升高	13(43.3)	10(33.3)	3(10.0)	0(0)	0(0)
呕吐	10(33.3)	7(23.3)	2(6.7)	1(3.3)	0(0)
蛋白尿	11(36.7)	7(23.3)	3(10.0)	1(3.3)	0(0)
高血压	10(33.3)	8(26.7)	2(6.7)	0(0)	0(0)
腹泻	3(10.0)	2(6.7)	1(3.3)	0(0)	0(0)
手足综合征	2(6.7)	1(3.3)	1(3.3)	0(0)	0(0)

[1]	Cao W, Chen HD, Yu YW, et al. Changing profiles of cancer burden worldwide and in China: A secondary analysis of the global cancer statistics 2020[J]. Chin Med J (Engl), 2021, 134(7): 783-791.
[2]	Bastiaenen VP, Aalbers A, Arjona-Sánchez A, et al. Risk of metachronous peritoneal metastases in patients with pT4a versus pT4b colon cancer: An international multicentre cohort study[J]. Eur J Surg Oncol, 2021, 47(9): 2405-2413.
[3]	Scott AJ, Messersmith WA, Jimeno A. Apatinib: A promising oral antiangiogenic agent in the treatment of multiple solid tumors[J]. Drugs Today (Barc), 2015, 51(4): 223-229.
[4]	Lan CY, Wang Y, Xiong Y, et al. Apatinib combined with oral etoposide in patients with platinum-resistant or platinum-refractory ovarian cancer (AEROC): A phase 2, single-arm, prospective study[J]. Lancet Oncol, 2018, 19(9): 1239-1246.
[5]	Song Z, Yu X, Lou G, et al. Salvage treatment with Apatinib for advanced non-small-cell lung cancer[J]. Onco Targets Ther, 2017, 10: 1821-1825.
[6]	Bi M, Yang J, Wang Y, et al. Successful treatment of metastatic colorectal cancer with Apatinib: report of two cases and literature review[J]. Onco Targets Ther, 2018, 11: 883-890.
[7]	刘伟, 安杰, 智亮辉, 等. 阿帕替尼联合化疗对转移性大肠癌的有效性及安全性评价[J].中国现代普通外科进展, 2023, 26(3): 225-228, 233.
[8]	Ajani JA, D’amico TA, Bentrem DJ, et al. Gastric cancer, Version 2.2022, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2022, 20(2): 167-192.
[9]	Benson AB, Venook AP, Al-hawary MM, et al. Rectal cancer, Version 2.2022, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2022, 20(10): 1139-1167.
[10]	Gosavi R, Chia C, Michael M, et al. Neoadjuvant chemotherapy in locally advanced colon cancer: A systematic review and meta-analysis[J]. Int J Colorectal Dis, 2021, 36(10): 2063-2070.
[11]	Morton D, Seymour M, Magill L, et al. Preoperative chemotherapy for operable colon cancer: mature results of an international randomized controlled trial[J]. J Clin Oncol, 2023, 41(8): 1541-1552.
[12]	Aziz MA, Serya RA, Lasheen DS, et al. Discovery of potent VEGFR-2 inhibitors based on furopyrimidine and thienopyrimidne scaffolds as cancer targeting agents[J]. Sci Rep, 2016, 6: 24460.
[13]	Yu X, Fan H, Jiang X, et al. Apatinib induces apoptosis and autophagy via the PI3K/AKT/mTOR and MAPK/ERK signaling pathways in neuroblastoma[J]. Oncol Lett, 2020, 20(4): 52.
[14]	Liu K, Ren T, Huang Y, et al. Apatinib promotes autophagy and apoptosis through VEGFR2/STAT3/BCL-2 signaling in osteosarcoma[J]. Cell Death Dis, 2017, 8(8): e3015.
[15]	Lee JJ, Chu E. Sequencing of antiangiogenic agents in the treatment of metastatic colorectal cancer[J]. Clin Colorectal Cancer, 2014, 13(3): 135-144.
[16]	Li J, Zhao X, Chen L, et al. Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies[J]. BMC Cancer, 2010, 10: 529.
[17]	Wu Q, Qian W, Sun X, et al. Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021[J]. J Hematol Oncol, 2022, 15(1): 143.
[18]	Arredondo J, Pastor E, Simó V, et al. Neoadjuvant chemotherapy in locally advanced colon cancer: A systematic review[J]. Tech Coloproctol, 2020, 24(10): 1001-1015.
[19]	Yuan Y, Xiao WW, Xie WH, et al. Neoadjuvant chemoradiotherapy for patients with unresectable radically locally advanced colon cancer: A potential improvement to overall survival and decrease to multivisceral resection[J]. BMC Cancer, 2021, 21(1): 179.
[20]	杨宇光, 唐辉, 谭志明, 等. 仑伐替尼、PD-1抑制剂联合肝动脉栓塞灌注化疗治疗不可切除肝癌疗效[J/OL]. 中华肝脏外科手术学电子杂志, 2023, 12(1): 55-60.

[1]	广东省医学会乳腺病学分会(广东省医学会乳腺病学分会青年委员会), 长江学术带乳腺联盟, 重庆市医学会乳腺病分会, 广东省预防医学会乳腺癌防治专业委员会. 三阴性乳腺癌新辅助铂类应用专家共识(2023版)[J]. 中华乳腺病杂志(电子版), 2024, 18(01): 1-10.
[2]	李晓鸥, 杨鹤鸣, 王国栋, 林海冠, 杨建武. 不同入路腹腔镜左半结肠癌根治术治疗效果对比[J]. 中华普外科手术学杂志(电子版), 2024, 18(04): 377-380.
[3]	孙龙凤, 侯高峰, 王幼黎, 刘磊. 腹腔镜下右半结肠癌D3根治术中SMA或SMV入路的选择[J]. 中华普外科手术学杂志(电子版), 2024, 18(04): 438-441.
[4]	金田力, 袁文正, 付涛. 单孔腹腔镜右半结肠癌根治术后尿管拔除时机探讨[J]. 中华普外科手术学杂志(电子版), 2024, 18(03): 271-274.
[5]	杜彦斌, 黄涛, 寇天阔, 石英. 双镜联合根治术与腹腔镜根治术在早期结肠癌患者中的应用效果[J]. 中华普外科手术学杂志(电子版), 2024, 18(03): 275-278.
[6]	张聃, 王毅, 冯文迪, 方兴中. 完整结肠系膜切除术与传统根治术治疗结肠癌对患者生存期的影响观察[J]. 中华普外科手术学杂志(电子版), 2024, 18(03): 279-282.
[7]	李娇娇, 张军, 徐顺. 全程新辅助治疗联合全直肠系膜切除术对局部进展期直肠癌预后的影响研究[J]. 中华普外科手术学杂志(电子版), 2024, 18(03): 283-286.
[8]	王东阳, 林琳, 娄熙彬. SII对局部进展期胃癌nCRT＋腹腔镜胃癌根治术后并发症及预后的影响研究[J]. 中华普外科手术学杂志(电子版), 2024, 18(03): 315-318.
[9]	沈海龙, 张建国, 邵一阳, 周晓超, 郭春来, 匡哲. 局部进展期低位直肠癌伴侧方淋巴短径<10 mm新辅助治疗后TME+LLND术的临床研究[J]. 中华普外科手术学杂志(电子版), 2024, 18(02): 192-195.
[10]	胡剑平, 王振乾, 张龙, 尹任其, 陈涵, 赵任, 吕强. 尾侧中间联合入路与尾侧入路在腹腔镜右半结肠癌根治术中的应用对比[J]. 中华普外科手术学杂志(电子版), 2024, 18(02): 196-199.
[11]	燕速, 霍博文, 徐惠宁. 4K荧光腹腔镜扩大右半结肠CME+D3根治术及No.206、No.204组淋巴结清扫术[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 14-14.
[12]	陈亚军, 姜玉娟, 周思成, 陈海鹏, 王征, 周海涛, 毕建军, 冯强, 郑朝旭, 姜争, 刘正, 梁建伟, 裴炜, 张海增, 汤坚强, 刘骞, 王锡山. 重组改构人肿瘤坏死因子用于进展期结肠癌患者术中腹腔灌注治疗的近期安全性及可行性分析[J]. 中华结直肠疾病电子杂志, 2024, 13(02): 94-100.
[13]	连彦军, 宋志岗, 范晓斌, 胡延伟, 范现英, 马竞优, 甄金朋, 杨宁豹. 肠减压后腹腔镜手术治疗右半结肠癌合并急性肠梗阻的临床观察[J]. 中华结直肠疾病电子杂志, 2024, 13(02): 129-134.
[14]	谢尔盖·叶菲托夫, 曹宇, 关旭, 刘正, 波琳娜·帕诺娃, 王锡山. 单孔经腹膜后入路行保留左结肠动脉的乙状结肠癌根治术(附视频)[J]. 中华结直肠疾病电子杂志, 2024, 13(02): 166-170.
[15]	李凯, 朱志, 周海涛, 王俊, 杨野, 赵鑫, 谷金蓉, 智冬梅, 王世洋, 高梓茗, 张鑫炜, 赵睿涵, 王锡山, 王振宁. 经自然腔道取标本手术（NOSES）在结直肠癌日间手术中的应用探索[J]. 中华结直肠疾病电子杂志, 2024, 13(01): 63-67.

阅读次数

全文

摘要

选择文件类型/文献管理软件名称

选择包含的内容

Apatinib combined with neoadjuvant chemotherapy in locally advanced colon cancer: A clinical efficacy study

模态框（Modal）标题

选择文件类型/文献管理软件名称

选择包含的内容

Apatinib combined with neoadjuvant chemotherapy in locally advanced colon cancer: A clinical efficacy study